Breaking News
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Aphria's May Surge In Stark Contrast To Cannabis Sector Peers

By (Brenda O'Farrell/ MarketsMay 28, 2019 02:50AM ET
Aphria's May Surge In Stark Contrast To Cannabis Sector Peers
By (Brenda O'Farrell/   |  May 28, 2019 02:50AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

Shares of Canadian medical cannabis producer Aphria Inc. (NYSE:APHA), (TSX:APHA) soared at the end of last week, gaining more than 14.5% Friday on news via MarketWatch that New York investment bank Jeffries initiated coverage of the stock, issuing a strong buy rating.

APHA 300 Minute Chart
APHA 300 Minute Chart

The Ontario-based licensed producer of medical pot and marijuana-based oils saw its share price go from U.S.$6.79 to U.S.$7.35 (CAD$8.62 to CAD$9.87) at the close, as Jeffries analyst Owen Bennett issued a price target of $11 (CAD$15), which would represent an almost 52% additional rise from Friday’s close.

“On our strategic scorecard, Aphria scores highly, and third overall behind only Canopy (NYSE:CGC), (TSX:WEED) and Aurora (NYSE:ACB),(TSX:ACB),” Bennett wrote in statement to clients.

In the past year, Aphria, which, with a current market cap of $1.93B, has consistently been in the top 10 North American cannabis companies by valuation, has also been considered one of the most under-performing stocks in the industry.

One of the reasons behind the stock’s poor performance can be attributed to governance issues, particularly negative headlines involving the September acquisition of South American LATAM Holdings last year, and claims by short sellers that the deal was priced too high. The allegations caused the stock's price to waver and the company to launch an internal investigation.

The review concluded the deal was within an acceptable range but discounted rates were applied. In January it was announced that Aphria CEO Vic Neufeld and company co-founder Cole Cacciavillani would “transition out of their executive roles” in the coming months. However, they remain on the board.

In the first five months of this year, Aphria shares increased 20%, but are still down 17.2% from this time last year when it saw a price peak of U.S.$16.50 in the fall (C$21.70) just before marijuana was legalized in Canada. It’s highest level in the post-legalization period this year was hit in February, when shares reached U.S.$10.84 (C$14.21).

Adding to the stock's momentum: positive news last week that Aphria had been granted its fifth cultivation license in Germany. Germany is currently the largest cannabis market in the European Union. Last year, its medicinal marijuana market was worth U.S.$73 million. By 2023, it will be valued at U.S. $2.7 billion, according to estimates.

The German licenses to produce medical cannabis had been conditionally awarded in April, and confirmed May 21 following a review by a German court. The move means Aphria is the only licensed producer of all three of the legal strains of medical cannabis in Germany.

These licenses essentially function as contracts to supply a minimum of 4,000 kilograms of domestically grown cannabis that will be sold to the German government’s Institute for Drugs and Medical Devices, and supplied to wholesalers for distribution to pharmacies. Aphria’s contracts cover a four-year period that begins in 2020.

Germany issued a total of 13 such licenses, with a maximum of five allowed to a single producer, according to government guidelines. In addition to Aphria’s licenses, five were granted to Edmonton-Based Aurora Cannabis and three went to Berlin-based producer Denecan.

Although Aphria is poised to finish the month on a high note, overall, May has not been stellar for the pot sector. To put it in perspective, the industry has seen more downs than ups, with trends largely flat to lower for most of the stocks in the space.

Among the biggest players, Tilray (NASDAQ:TLRY) shares dropped 14.4% so far this month, while Canopy has slumped 12.6%. Cronos Group (NASDAQ:CRON), (TSX:CRON) lost 12.6% and Aurora Cannabis shed 8%.

Among the smaller players, Quebec-based Hexo (NYSE:HEXO), (TSX:HEXO) trimmed 16.8% so far this month, while CannTrust Holdings (NYSE:CTST),(TSX:TRST) dropped 14.6%.

Aphria's May Surge In Stark Contrast To Cannabis Sector Peers

Related Articles

Aphria's May Surge In Stark Contrast To Cannabis Sector Peers

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email